Skip to main content
David R. Gastfriend, MD, Psychiatry, Wareham, MA

David R.GastfriendMDDFASAM

Psychiatry Wareham, MA

Addiction

Chief Architect, ASAM's CONTINUUM(TM); Scientific Advisor, Treatment Research Institute

Dr. Gastfriend is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Gastfriend's full profile

Already have an account?

  • Office

    8 Beach Plum Ln
    Wareham, MA 02571
    Phone+1 617-283-6495

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1984
  • Presbyterian Medical Center of the University of Pennsylvania Health System
    Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 1980 - 1981
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1980
  • Haverford College
    Haverford CollegeBS, 1972 - 1976

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1982 - 2026
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • ASAE Gold Award American Society of Association Executives, 2016
  • Distinguished Fellow American Society of Addiction Medicine, 2016
  • John P. McGovern, M.D. Award and Lecture for highly meritorious contributions to addiction and society in public policy, treatment, research or prevention. American Society of Addiction Medicine, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Attitudes and practices on the use of extended-release naltrexone in criminal justice settings  
    Festinger DS, Dugosh KL, Gastfriend DR, Sierka C, Drug Alc Dependence, 1/1/2017
  • Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence  
    Earley PH, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR, J Addiction Medicine, 1/1/2017
  • Specialized community disease management to reduce substance use and hospital readmissions  
    Chambers JE, Brooks AC, Morrison MF, McKay JR, Gastfriend DR, Drug Alc Dependence, 1/1/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Commentary on Nonpharmacologic Approaches to Substance Abuse Treatment
    Gastfriend, DR, Abstracts of Clinical Care Guidelines, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, 1/1/1998
  • Categorical vs. dimensional determination of alcoholic subtype and correlation with severity and personality
    Gastfriend DR, Lex BW, Waldman J, Mendelson J, Alcoholism: Clin Exp Research, 1/1/1990

Other

  • New Horizons for Treatment Strategies 
    Creed M, Crystal RG, Gastfriend DR, Tyndale RF, The New York Academy of Sciences. The Addicted Brain and New Treatment Frontiers: Sixth Annual Aspen
    www.nyas.org/addiction2016-eB
    1/1/2016
  • Treatment matching in substance use disorders (audiotape journal) 
    Gastfriend, DR, Practical Reviews in Psychiatry
    1/1/1996
  • Diagnosis and treatment matching in alcoholism (audiotape journal) 
    Gastfriend, DR, Practical Reviews in Psychiatry
    1/1/1989
  • Join now to see all

Press Mentions

  • ANNOUNCEMENT: Intent Solutions Announces New Advisory Board Member-- David Gastfriend
    ANNOUNCEMENT: Intent Solutions Announces New Advisory Board Member-- David GastfriendJanuary 17th, 2017
  • PODCAST: David Gastfriend Discusses the Importance of the ASAM Criteria
    PODCAST: David Gastfriend Discusses the Importance of the ASAM CriteriaDecember 8th, 2014
  • ASAM Criteria Software Plenary Outlines Impending Product Launch
    ASAM Criteria Software Plenary Outlines Impending Product LaunchOctober 13th, 2014
  • Join now to see all

Grant Support

  • A Simple Large Trial of Patient‐Centered Care for Opioid Use Disorders in Federally Qualified Healthcare CentersPCORI - The Patient-Centered Outcomes Research Institute2017–2022
  • Improving Drug Abuse Treatment Planning CriteriaNational Institute On Drug Abuse2000–2004
  • Core--ClinicalNational Institute On Drug Abuse1997–2002
  • Validity Of The ASAM Criteria For Drug Abuse TreatmentNational Institute On Drug Abuse1994–2000

Professional Memberships

Industry Relationships

  • Consultant, IBM Watson - Truven Health AnalyticsProvide health outcomes research and policy guidance and technical assistance to IBM Watson research & evaluation staff and state Medicaid leadership, on behalf of U.S. Centers for Medicare & Medicaid Services (CMS)2016 - Present
  • Consultant, Rand Corp.Provide scientific expertise for algorithm mapping in clinical decision support and analysis.2016 - Present
  • Consultant, BioCorRx, Inc.2016 - Present
  • Consultant, Indivior, Inc.2016 - Present
  • Scientific Advisory Board Member, Recovery Corporation of America, Inc.2016 - 2017
  • Consultant, Purdue Pharma2016 - 2016
  • Consultant, Kaleo, Inc.2016 - 2016
  • Vice President, Alkermes, Inc.Provided guidance and oversight for the development of monthly injectable naltrexone, addressing basic, clinical RCT, effectiveness, health economic, and criminal justice research for this new formulation, which achieved FDA-approval in the treatment of both alcohol and opioid dependence.Disclosure: Consultant; shareholder2005 - 2013